Navigation Links
Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
Date:3/5/2009

Unless appealed, delisting scheduled for March 12, 2009

NEW YORK, March 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that it received a letter from the Staff of The Nasdaq Stock Market indicating that the Company had failed to regain compliance with Nasdaq Marketplace Rule 4310(c)(3), which requires the Company to have a minimum of $2,500,000 in stockholders' equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years, for continued listing on The Nasdaq Capital Market. The Staff has therefore determined to delist the Company's common stock from The Nasdaq Capital Market effective at the opening of business on March 12, 2009.

The Company is currently evaluating whether to appeal the Staff's determination to a hearing before a Nasdaq Listing Qualifications Panel, which request would stay the delisting of the Company's securities pending the Panel's decision. The Company must make an appeal request by 4:00 pm (EST) on March 10, 2009. If the Company decides to appeal, the Company would expect the hearing to be scheduled for April 2009. The Staff previously granted the Company a 105-day extension to regain compliance with Marketplace Rule 4310(c)(3). If the Company decides to move forward with an appeal, it would be asking that the Panel provide additional time to regain compliance with Nasdaq Marketplace Rule 4310(c)(3). There can be no assurance that such a request will be granted or that the Panel will permit the Company to continue to list its common stock on The Nasdaq Capital Market.

If the Company is delisted from The Nasdaq Capital Market, its common stock may be traded over-the-counter on the OTC Bulleti
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... SAN DIEGO, Oct. 20 Cardium Therapeutics,(Amex: ... Inc., announced,today that it has received 510(k) clearance ... market the RapidBlue(TM) System, an endovascular,temperature modulation device. ... to manage and control patient body temperature.,This new ...
... joins Pierpoint International as Global VP of Recruitment Operations and Diversity ... ... -- Pierpoint International is pleased to announce the appointment of Robert ... most recently served as AVP of Staffing and Diversity for USAA, ...
... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today announced ... a Phase I multiple dose clinical trial of NGX426, ... The trial is,designed to evaluate the safety, tolerability and ... days. NGX426 has been,safely administered to more than 150 ...
Cached Biology Technology:Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 2Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 3Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 4Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 5Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 6Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 7Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 8Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 9Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 10Robert Cantu Appointed Vice President of Pierpoint International 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... athletes looking to boost performance comes in the form of ... for its popularity is twofold says Scott Forbes, a doctoral ... for nitric oxide that is known to improve blood flow, ... to working muscles and assist with metabolic waste product removal. ...
... Bethesda, MD The Association for Molecular Pathology ... to exclusively license the subject matter of a cancer-related ... written remarks were submitted to NIH in response to ... entitled, "Prospective Grant of Exclusive License: The Development of ...
... of engineering principles to understand and treat medical conditions ... damage to the brain caused by a traumatic injury. ... presented in a special issue of Journal of ... Liebert, Inc. ( http://www.liebertpub.com ) The entire issue is ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3AMP opposes exclusive licensing of NIH proteomics patent 2Bioengineering yields new approaches for diagnosing and treating traumatic brain injury 2
... Camera hood with 5.6" TFT color screen, ... digimage system use digital camera with 8.0 mega ... space requirements and small budget. View image from ... it's specific feature. It is suitable to capture ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
Biology Products: